erbb 2 receptor

Summary

Summary: A cell surface protein-tyrosine kinase receptor that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor (RECEPTOR, EPIDERMAL GROWTH FACTOR), the erbB-3 receptor (RECEPTOR, ERBB-3) and the erbB-4 receptor. Activation of the erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB receptor family members.

Top Publications

  1. ncbi American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 25:118-45. 2007
  2. ncbi Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
  3. ncbi Untangling the ErbB signalling network
    Y Yarden
    Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
    Nat Rev Mol Cell Biol 2:127-37. 2001
  4. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
  5. ncbi ERBB receptors and cancer: the complexity of targeted inhibitors
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Nat Rev Cancer 5:341-54. 2005
  6. ncbi Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    D J Slamon
    Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
    N Engl J Med 344:783-92. 2001
  7. ncbi Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
  8. ncbi Trastuzumab--mechanism of action and use in clinical practice
    Clifford A Hudis
    Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 357:39-51. 2007
  9. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
  10. ncbi Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Charles E Geyer
    Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    N Engl J Med 355:2733-43. 2006

Detail Information

Publications258 found, 100 shown here

  1. ncbi American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 25:118-45. 2007
    ..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker...
  2. ncbi Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
    ..Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B...
  3. ncbi Untangling the ErbB signalling network
    Y Yarden
    Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
    Nat Rev Mol Cell Biol 2:127-37. 2001
    ..Likewise, small-molecule enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clinical testing. What can this pathway teach us about translating basic science into clinical use?..
  4. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
    ..The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers...
  5. ncbi ERBB receptors and cancer: the complexity of targeted inhibitors
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Nat Rev Cancer 5:341-54. 2005
    ..We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response...
  6. ncbi Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    D J Slamon
    Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
    N Engl J Med 344:783-92. 2001
    ..The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor...
  7. ncbi Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  8. ncbi Trastuzumab--mechanism of action and use in clinical practice
    Clifford A Hudis
    Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 357:39-51. 2007
  9. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
    ..To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer...
  10. ncbi Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Charles E Geyer
    Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    N Engl J Med 355:2733-43. 2006
    ..In this trial, we compared lapatinib plus capecitabine with capecitabine alone in such patients...
  11. doi Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...
  12. ncbi Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
    R A Clynes
    Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Ave, New York, New York 10021, USA
    Nat Med 6:443-6. 2000
    ....
  13. ncbi Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:5367-74. 2004
    ..Currently, there exist clinical assays that identify ER+/luminal and HER2-overexpressing tumors, and we sought to develop a clinical assay for breast basal-like tumors...
  14. pmc The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
    Thomas Holbro
    Friedrich Miescher Institute, P O Box 2543, 4002 Basel, Switzerland
    Proc Natl Acad Sci U S A 100:8933-8. 2003
    ..Furthermore, we identify ErbB3's role, which is to couple active ErbB2 to the phosphatidylinositol 3-kinase/protein kinase B pathway. Thus, the ErbB2/ErbB3 dimer functions as an oncogenic unit to drive breast tumor cell proliferation...
  15. ncbi Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Martine J Piccart-Gebhart
    Medicine Department, Jules Bordet Institute, Blvd de Waterloo 125, 1000 Brussels, Belgium
    N Engl J Med 353:1659-72. 2005
    ..We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy...
  16. pmc Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
    Pratyaksha Wirapati
    Swiss Institute of Bioinformatics, Batiment Genopode, University of Lausanne, 1015 Lausanne, Switzerland
    Breast Cancer Res 10:R65. 2008
    ....
  17. ncbi Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
    Matthew C Franklin
    Department of Protein Engineering, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94114 USA
    Cancer Cell 5:317-28. 2004
    ..We have also shown that conserved residues previously shown to be necessary for EGF receptor homodimerization may be dispensible for ErbB2-ErbB3 heterodimerization...
  18. pmc Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
    C T Guy
    Institute for Molecular Biology and Biotechnology, McMaster University, Hamilton, Ontario, Canada
    Proc Natl Acad Sci U S A 89:10578-82. 1992
    ..Interestingly, many of the tumor-bearing transgenic mice developed secondary metastatic tumors in the lung. These observations suggest that overexpression of the unactivated neu protein can induce metastatic disease after long latency...
  19. pmc Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
    Natalia V Sergina
    Department of Medicine, University of California, San Francisco 94143, USA
    Nature 445:437-41. 2007
    ..The biologic marker with which to assess the efficacy of HER TKIs should be the transphosphorylation of HER3 rather than autophosphorylation...
  20. ncbi Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
    Hyun Soo Cho
    Department of Biophysics and Biophysical Chemistry, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, Maryland 21205, USA
    Nature 421:756-60. 2003
    ..Herceptin binds to the juxtamembrane region of HER2, identifying this site as a target for anticancer therapies...
  21. ncbi Relevance of breast cancer cell lines as models for breast tumours: an update
    Marc Lacroix
    Laboratoire Jean Claude Heuson de Cancérologie Mammaire, Institut Jules Bordet, Universite Libre de Bruxelles, Bruxelles, Belgium
    Breast Cancer Res Treat 83:249-89. 2004
    ..Investigations on additional specific lines are expected to improve our knowledge of BCC and of the dialogue that these maintain with their surrounding normal cells in vivo...
  22. ncbi HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues
    Marilyn A Owens
    IMPATH, Inc, Los Angeles, CA 90066, USA
    Clin Breast Cancer 5:63-9. 2004
    ..The relationship between level of HER2 amplification and clinical outcome will require reanalysis of pivotal trial data...
  23. ncbi Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
    Jiang Shou
    The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 96:926-35. 2004
    ..We used a breast cancer model system with high expression of AIB1 and HER2 to investigate the possible mechanisms underlying this resistance...
  24. ncbi Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
    Rita Nahta
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030 4009, USA
    Nat Clin Pract Oncol 3:269-80. 2006
    ..Novel therapies targeted against these aberrant molecular pathways offer hope that the effectiveness and duration of response to trastuzumab can be greatly improved...
  25. ncbi Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group
    Michael A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Rockledge, PA, USA
    J Clin Oncol 21:283-90. 2003
    ..To evaluate the feasibility, toxicity, and efficacy of single-agent monoclonal antibody therapy targeting the human epidermal growth factor receptor 2 (HER2)/neu receptor in ovarian and primary peritoneal carcinoma...
  26. ncbi Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer
    Bruce G Haffty
    Department of Radiation Oncology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903 2681, USA
    J Clin Oncol 24:5652-7. 2006
    ..To determine the prognostic significance of triple negative breast cancers with respect to locoregional relapse and distant metastasis in conservatively managed breast cancer patients...
  27. ncbi Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    David B Agus
    Cedars Sinai Prostate Cancer Center, Los Angeles, California 90048, USA
    Cancer Cell 2:127-37. 2002
    ..We demonstrate that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment...
  28. ncbi Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
    Johanna C Bendell
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 97:2972-7. 2003
    ..Women with HER-2 overexpressing metastatic breast carcinoma benefit from trastuzumab-based therapy, but trastuzumab does not cross the blood-brain barrier. The authors characterized central nervous system (CNS) disease in these women...
  29. ncbi The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
    Lisa A Carey
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Clin Cancer Res 13:2329-34. 2007
    ..Gene expression analysis identifies several breast cancer subtypes. We examined the relationship of neoadjuvant chemotherapy response to outcome among these breast cancer subtypes...
  30. ncbi Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    Kathy Miller
    Indiana University Cancer Center, Indianapolis, USA
    N Engl J Med 357:2666-76. 2007
    ....
  31. ncbi A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
    Katrien Berns
    Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Cancer Cell 12:395-402. 2007
    ..Thus, assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to respond to trastuzumab-based therapy...
  32. ncbi Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis
    Yan M Li
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Cell 6:459-69. 2004
    ..These results provide a plausible mechanism for HER2-mediated breast tumor metastasis and establish a functional link between HER2 and CXCR4 signaling pathways...
  33. ncbi Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
    Y Lu
    Department of Oncology, Jewish General Hospital, and McGill University, Montreal, PQ, Canada
    J Natl Cancer Inst 93:1852-7. 2001
    ..Thus, strategies that target IGF-IR signaling may prevent or delay development of resistance to trastuzumab...
  34. ncbi PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    Yoichi Nagata
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 6:117-27. 2004
    ..Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance...
  35. ncbi Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry
    Katrina R Bauer
    Public Health Institute California Cancer Registry, Sacramento, California 95815 4402, USA
    Cancer 109:1721-8. 2007
    ..The triple-negative phenotype is important because of its relation to the basal-like subtype of breast cancer...
  36. ncbi Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells
    B P Zhou
    Department of Molecular and Cellular Oncology, Breast Cancer Basic Research Program, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Nat Cell Biol 3:245-52. 2001
    ..Our results indicate that HER-2/neu induces cytoplasmic localization of p21Cip1/WAF1 through activation of Akt to promote cell growth, which may have implications for the oncogenic activity of HER-2/neu and Akt...
  37. ncbi Brain metastases: the HER2 paradigm
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 13:1648-55. 2007
    ..Finally, new developments in systemic approaches to the treatment of CNS disease, including cytotoxic chemotherapy and targeted therapy, are explored...
  38. doi Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
    Mary Jo Lund
    Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road, NE, Atlanta, GA 30322, USA
    Breast Cancer Res Treat 113:357-70. 2009
    ..This study examines association of the ER/PR/HER2 subtypes with race and breast cancer survival...
  39. ncbi HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
    B P Zhou
    Department of Molecular and Cellular Oncology, Breast Cancer Basic Research Program, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Nat Cell Biol 3:973-82. 2001
    ..Our study indicates that blocking the Akt pathway mediated by HER-2/neu would increase the cytotoxic effect of DNA-damaging drugs in tumour cells with wild-type p53...
  40. pmc Targeting HER proteins in cancer therapy and the role of the non-target HER3
    A C Hsieh
    Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
    Br J Cancer 97:453-7. 2007
    ..This review presents the current evidence highlighting the role of HER3 in tumorigenesis and its role in mediating resistance to inhibitors of EGFR and HER2...
  41. ncbi Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
    Maurizio Scaltriti
    Medical Oncology Program, Medical Oncology Department, Vall d Hebron University Hospital and Research Institute, Barcelona 08035, Spain
    J Natl Cancer Inst 99:628-38. 2007
    ....
  42. ncbi HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
    Christiane Knuefermann
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
    Oncogene 22:3205-12. 2003
    ....
  43. pmc NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis
    Debajit K Biswas
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:10137-42. 2004
    ....
  44. ncbi The deaf and the dumb: the biology of ErbB-2 and ErbB-3
    Ami Citri
    Department of Biological Regulation, The Weizmann Institute of Science, 76100, Rehovot, Israel
    Exp Cell Res 284:54-65. 2003
    ..This review highlights recent structural insights into the mechanism of ligand-induced heterodimer formation, and concentrates on signaling pathways employed by ErbB-2 and ErbB-3 in normal and in malignant cells...
  45. ncbi Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells
    Janice M Knowlden
    Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3XF, United Kingdom
    Endocrinology 144:1032-44. 2003
    ..These results demonstrate that TAM-R MCF-7 cell growth is mediated by the autocrine release and action of an EGFR-specific ligand inducing preferential EGFR/c-erbB2 dimerization and downstream activation of the ERK pathway...
  46. ncbi Prognostic value of ERBB family mRNA expression in breast carcinomas
    Ivan Bieche
    Laboratoire d Oncogénétique INSERM E0017, Centre Rene Huguenin, St Cloud, France
    Int J Cancer 106:758-65. 2003
    ....
  47. doi Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study
    Bella Kaufman
    Chaim Sheba Medical Center, Tel Hashomer, Israel
    J Clin Oncol 27:5529-37. 2009
    ..TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2)/hormone receptor-copositive metastatic breast cancer (MBC)...
  48. ncbi PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
    Lao H Saal
    Integrated Program in Cellular, Molecular, and Biophysical Studies, Institute for Cancer Genetics, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Cancer Res 65:2554-9. 2005
    ..Thus, mutation of PIK3CA is frequent, occurs early in carcinoma development, and has prognostic and therapeutic implications...
  49. ncbi Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Cancer Invest 22:858-65. 2004
    ....
  50. ncbi Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
    W J Muller
    Harvard Medical School Department of Genetics, Boston, Massachusetts 02115
    Cell 54:105-15. 1988
    ....
  51. doi HER2 status and benefit from adjuvant trastuzumab in breast cancer
    Soonmyung Paik
    N Engl J Med 358:1409-11. 2008
  52. pmc Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer
    P M Siegel
    Institute for Molecular Biology and Biotechnology, McMaster University, Hamilton, Ontario, Canada L8S 4K1
    EMBO J 18:2149-64. 1999
    ....
  53. pmc Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
    Marc Tischkowitz
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    BMC Cancer 7:134. 2007
    ..The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested...
  54. ncbi Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
    M Carolina Gutierrez
    Breast Center and Department of Pathology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:2469-76. 2005
    ..To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clinical breast cancer specimens and in a xenograft model before tamoxifen and at tumor progression as a possible mechanism for tamoxifen resistance...
  55. ncbi Requirement for neuregulin receptor erbB2 in neural and cardiac development
    K F Lee
    Clayton Foundation Laboratories for Peptide Biology, Salk Institute, La Jolla, California 92037, USA
    Nature 378:394-8. 1995
    ..DiI retrograde tracing revealed that the development of motor nerves was also compromised. Our results demonstrate the importance of erbB2 in neural and cardiac development...
  56. doi A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy
    Si Tuen Lee-Hoeflich
    Department of Pathology, Genentech, Inc, South San Francisco, CA 94080, USA
    Cancer Res 68:5878-87. 2008
    ....
  57. ncbi FOXA1 expression in breast cancer--correlation with luminal subtype A and survival
    Sunil Badve
    Department of Pathology, Indiana University School of Medicine, Indianapolis, USA
    Clin Cancer Res 13:4415-21. 2007
    ..It segregates with genes that characterize the luminal subtypes in DNA microarray analyses. The utility of FOXA1 as a possible independent prognostic factor has not been determined in breast cancers...
  58. doi Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
    Christine Desmedt
    Medical Oncology Department, Jules Bordet Institute
    Clin Cancer Res 14:5158-65. 2008
    ..Here we aimed to perform a comprehensive meta-analysis integrating both clinicopathologic and gene expression data, focusing on the main molecular subtypes...
  59. ncbi Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database
    Gloria J Morris
    Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA
    Cancer 110:876-84. 2007
    ..Breast carcinomas in African-American patients appear to be more aggressive than in Caucasian patients due to multifactorial differences...
  60. ncbi Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy
    Xiaojiang Cui
    Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 23:7721-35. 2005
    ..Finally, we will consider the clinical implications of these observations...
  61. pmc Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice
    K Boggio
    Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy
    J Exp Med 188:589-96. 1998
    ....
  62. doi Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:1368-76. 2008
    ..This study directly compares the prognostic significance between three- and five-biomarker surrogate panels to define intrinsic breast cancer subtypes, using a large clinically annotated series of breast tumors...
  63. ncbi Identification of molecular apocrine breast tumours by microarray analysis
    Pierre Farmer
    Swiss Institute of Bioinformatics, Lausanne, Switzerland
    Oncogene 24:4660-71. 2005
    ..Our data show that it is possible with microarray data to divide mammary tumour cells into three groups based on steroid receptor activity: luminal (ER+ AR+), basal (ER- AR-) and molecular apocrine (ER- AR+)...
  64. ncbi Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
    Wenle Xia
    Department of Discovery Medicine, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, North Carolina, NC 27709 3398, USA
    Oncogene 21:6255-63. 2002
    ....
  65. pmc Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
    L Arnould
    Department of Pathology, Centre G F Leclerc, Dijon 21000, France
    Br J Cancer 94:259-67. 2006
    ..These results suggest that trastuzumab plus taxanes lead to enhanced NK cell activity, which may partially account for the synergistic activity of trastuzumab and docetaxel in breast cancer...
  66. pmc Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
    Gustavo A Viani
    Department of Radiation Oncology, Faculdade de Medicina de Marilia, Faculty of Medicine of Marília FAMEMA, Marilia, Sao Paulo, Brazil
    BMC Cancer 7:153. 2007
    ..Here, we performed a meta-analysis of completed clinical trials of adjuvant trastuzumab in the adjuvant setting. Survival, recurrence, brain metastases, cardiotoxicity and directions for future research are discussed...
  67. ncbi Breast cancer molecular subtypes respond differently to preoperative chemotherapy
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 11:5678-85. 2005
    ..The goal of this research was to determine if these different molecular subtypes of breast cancer also respond differently to preoperative chemotherapy...
  68. ncbi Lung cancer: intragenic ERBB2 kinase mutations in tumours
    Philip Stephens
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Nature 431:525-6. 2004
    ..ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations...
  69. doi Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
    David L Shattuck
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Cancer Res 68:1471-7. 2008
    ..Our study suggests that a subset of Her2 (+) patients may benefit from combined inhibition of Her2 and Met...
  70. ncbi Triple-negative breast cancer: therapeutic options
    Susan Cleator
    Oncology Department, St Mary s Hospital Trust, London, UK
    Lancet Oncol 8:235-44. 2007
    ....
  71. ncbi Concordance among gene-expression-based predictors for breast cancer
    Cheng Fan
    Department of Genetics, University of North Carolina at Chapel Hill and Lineberger Comprehensive Cancer Center, Chapel Hill 27599, USA
    N Engl J Med 355:560-9. 2006
    ..Gene-expression-profiling studies of primary breast tumors performed by different laboratories have resulted in the identification of a number of distinct prognostic profiles, or gene sets, with little overlap in terms of gene identity...
  72. ncbi Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    Howard A Burris
    The Sarah Cannon Research Institute, 250 25th Avenue N, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 23:5305-13. 2005
    ....
  73. ncbi The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors
    Thomas P J Garrett
    Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, 3050, Parkville, Victoria, Australia
    Mol Cell 11:495-505. 2003
    ..Together, the data suggest a model in which ErbB2 is already in the activated conformation and ready to interact with other ligand-activated ErbB receptors...
  74. ncbi Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas
    Socorro Maria Rodriguez-Pinilla
    Breast and Gynecological Cancer Group, Molecular Pathology Programme and Department of Human Genetics, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Clin Cancer Res 12:1533-9. 2006
    ..The aim of this study was to determine whether basal-like phenotype and fascin were related in both sporadic and familial tumors and with prognosis in node-negative sporadic breast cancers...
  75. ncbi The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides
    Andrea B Motoyama
    Friedrich Miescher Institute, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Cancer Res 62:3151-8. 2002
    ....
  76. ncbi Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:1800-8. 2002
    ..To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2-overexpressing metastatic breast cancer. Efficacy was correlated with serum HER-2 extracellular domain (ECD) levels...
  77. ncbi Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer
    J S Nielsen
    University of Southern Denmark, Odense, Denmark
    Int J Gynecol Cancer 14:1086-96. 2004
    ..In the borderline group Her-2 and EGFR over-expression in combination, adjusted for age and p53, significantly improved the prognosis...
  78. ncbi HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability
    Ingo K Mellinghoff
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Cancer Cell 6:517-27. 2004
    ..Surprisingly, the downstream signaling pathway responsible for these effects appears to involve kinases other than Akt. These data suggest that the HER2/ERBB3 pathway is a critical target in hormone-refractory prostate cancer...
  79. ncbi Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
    Wenle Xia
    Department of Discovery Medicine, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709 3398, USA
    Oncogene 23:646-53. 2004
    ..Thus, p95ErbB2 represents a target for therapeutic intervention, and one that is sensitive to GW572016 therapy...
  80. ncbi Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity
    Douglas B Sawyer
    Cardiovascular Medicine Section, Department of Medicine, Boston Medical Center and Myocardial Biology Unit, Boston University School of Medicine, Boston, MA, USA
    Circulation 105:1551-4. 2002
    ....
  81. ncbi Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network
    Christoph A Ritter
    Institute of Pharmacology, University of Greifswald, Greifswald, Germany
    Clin Cancer Res 13:4909-19. 2007
    ..We have investigated mechanisms of acquired resistance to the HER2 antibody trastuzumab in BT-474 human breast cancer cells...
  82. ncbi Standardization of HER2 testing: results of an international proficiency-testing ring study
    Mitch Dowsett
    Academic Depertment of Biochemistry, Royal Marsden Hospital, London, UK
    Mod Pathol 20:584-91. 2007
    ..7-2.3 by at least one center. Equivocal immunohistochemistry and borderline FISH cases are difficult to interpret, even for highly experienced and validated laboratories, highlighting the need for quality-control procedures...
  83. ncbi Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study
    Harold J Burstein
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 21:46-53. 2003
    ..We conducted a pilot study of preoperative trastuzumab and paclitaxel, followed by surgery and adjuvant doxorubicin and cyclophosphamide chemotherapy in earlier stage breast cancer...
  84. ncbi Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice
    Elena Quaglino
    Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
    Cancer Res 64:2858-64. 2004
    ..These findings show that an appropriate vaccine effectively inhibits the progression of multifocal preneoplastic lesions...
  85. pmc Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
    G Pérez-Tenorio
    Department of Biomedicine and Surgery, Division of Oncology, Clinical Research Center, Faculty of Health Sciences, Linkoping University, SE 581 85 Linkoping, Sweden
    Br J Cancer 86:540-5. 2002
    ..004). The results suggest that activation of Akt may have prognostic relevance in breast cancer...
  86. pmc HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
    E Laughner
    Institute of Genetic Medicine, Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-3914, USA
    Mol Cell Biol 21:3995-4004. 2001
    ..These data provide a molecular basis for VEGF induction and tumor angiogenesis by heregulin-HER2 signaling and establish a novel mechanism for the regulation of HIF-1alpha expression...
  87. ncbi 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
    Ian Smith
    Royal Marsden Hospital, London, UK
    Lancet 369:29-36. 2007
    ..We investigated the drug's effect on overall survival after a median follow-up of 2 years in the Herceptin Adjuvant (HERA) study...
  88. ncbi High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates
    Gabriela Alexe
    The Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA
    Cancer Res 67:10669-76. 2007
    ..These data suggest that early-stage HER2+ cancers associated with lymphocytic infiltration are a biologically distinct subtype with an improved natural history...
  89. ncbi ErbB transmembrane tyrosine kinase receptors are differentially expressed throughout the adult rat central nervous system
    K M Gerecke
    Department of Neurobiology, The University of Alabama at Birmingham, 1720 Seventh Avenue South, Birmingham, AL 35294-0017, USA
    J Comp Neurol 433:86-100. 2001
    ..The continued expression of NRGs and their erbB receptors in mature brain also implies that these molecules perform important functions in the brain throughout life...
  90. doi Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab
    Alessandra Magnifico
    Molecular Biology Unit, Department of Experimental Oncology, IRCCS Foundation National Cancer Institute, Milan, Italy
    Clin Cancer Res 15:2010-21. 2009
    ....
  91. doi A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue
    Yining Shi
    Departments of Research and Development, Clinical Research, and Operations, Monogram Biosciences Inc, 345 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Diagn Mol Pathol 18:11-21. 2009
    ..The continuous measure of HER2 protein levels over a broad dynamic range, and the novel HER2 homodimer measure, are presently being assessed as predictive markers for responses to targeted HER2 therapy...
  92. doi Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy
    Paul L Nguyen
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 26:2373-8. 2008
    ..To determine whether breast cancer subtype is associated with outcome after breast-conserving therapy (BCT) consisting of lumpectomy and radiation therapy...
  93. doi Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer
    Michail Ignatiadis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Clin Cancer Res 14:2593-600. 2008
    ..To investigate the prognostic value of the molecular detection of circulating tumor cells (CTCs) using three markers [cytokeratin 19 (CK19), mammaglobin A (MGB1), and HER2] in early breast cancer...
  94. pmc Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53
    S W Beenken
    Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Ann Surg 233:630-8. 2001
    ..To assess the prognostic significance of molecular biomarkers, particularly c-erbB-2 and p53, through study of prospective clinical data and archival breast cancer tissues for women accrued to the Alabama Breast Cancer Project...
  95. doi HER-2 amplification is highly homogenous in gastric cancer
    Andreas H Marx
    Institute of Pathology, University Medical Center Hamburg Eppendorf, Germany
    Hum Pathol 40:769-77. 2009
    ..The high level of HER-2 amplification in combination with the homogeneity of its expression in primary and metastatic tumors argues for a possible therapeutic utility of trastuzumab in HER-2-amplified gastric adenocarcinomas...
  96. pmc neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice
    B Li
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520 8023, USA
    Mol Cell Biol 17:3155-63. 1997
    ..In these bitransgenic mice, we have recapitulated two common genetic lesions that occur in human breast cancer and have shown that p53 mutation is an important cooperating event in neu-mediated oncogenesis...
  97. doi Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
    Kimberly L Blackwell
    Duke University Medical Center, Durham, NC 27701, USA
    J Clin Oncol 28:1124-30. 2010
    ..EGF104900 compared the activity of lapatinib alone or in combination with trastuzumab in patients with ErbB2-positive, trastuzumab-refractory metastatic breast cancer (MBC)...
  98. pmc ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches
    Jin Qiang Chen
    Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Biochim Biophys Acta 1796:162-75. 2009
    ..Gaining better insights into these molecular pathways in TNBC may lead to identification of novel biomarkers and targets for development of diagnostic and therapeutic approaches for prevention and treatment of TNBC...
  99. ncbi HER-2/neu amplification is an independent prognostic factor in gastric cancer
    Dong Il Park
    Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
    Dig Dis Sci 51:1371-9. 2006
    ....
  100. doi Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases
    Patrick J Medina
    College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
    Clin Ther 30:1426-47. 2008
    ....
  101. ncbi The neuregulin-I/ErbB signaling system in development and disease
    Stefan Britsch
    Max Delbruck Center for Molecular Medicine MDC Berlin Buch, Germany
    Adv Anat Embryol Cell Biol 190:1-65. 2007
    ..In this review the basic biology of the Neuregulin-1/ErbB system and how it relates to the in vivo functions were discussed with special emphasis to transgenic techniques in mice...

Research Grants66

  1. Phage Display for Improved Peptide-based Tumor Targeting and Imaging Agents
    Susan L Deutscher; Fiscal Year: 2013
    ..This work is significant and relevant to the VA mission because the peptides discovered here may translate into novel prostate, breast, and ovarian cancer diagnostics and therapeutics for our veterans. ..
  2. Peptide-targeted alpha-particle emitting phage for ovarian cancer therapy.
    Thomas P Quinn; Fiscal Year: 2013
    ....
  3. BIOMEDICAL (BASIC)
    RICHARD TESTA; Fiscal Year: 2009
    ..These studies will form the foundation for Phase II studies aimed at developing Pb-based alpha-particle emitting ErbB-2-targeting peptides for the treatment of ovary, lung, and breast cancers. ..
  4. Low-Cost Digital Gene Expression System
    STEVEN JEFFREY GORDON; Fiscal Year: 2013
    ....
  5. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2005
    ..The results of the proposed studies may ultimately point to new directions of molecular therapies of breast cancer. ..
  6. Improved Peptide-based Tumor Targeting Agents Using Phage Display
    Susan L Deutscher; Fiscal Year: 2010
    ..The ability of the discovered molecules to reduce kidney uptake of radiolabeled peptides that bind the ErbB-2 receptor overexpressed on breast, ovarian, and lung tumors will be investigated in living animals. ..
  7. Mouse Models of ErbB-2 and Cyclin D1 in Prostate Cancer
    Christopher Albanese; Fiscal Year: 2002
    ..abstract_text> ..
  8. ERBB2 RECEPTOR SIGNALING AND BREAST CANCER METASTASIS
    Dihua Yu; Fiscal Year: 2002
    ..can be induced by growth signals associated with c-erbB-2 receptor and its ligand. ..
  9. MEASUREMENT OF RAS ACTIVATION IN LUNG CANCER
    Gerry Boss; Fiscal Year: 2000
    ..The work is, therefore, responsive to PA-98-022, "Exploratory Studies in Cancer Diagnostics." ..
  10. The effect of erbB-2 receptor antagonism on cardiac via*
    Luanda Grazette; Fiscal Year: 2005
    ..Understanding the role of this receptor, and its relationship to signaling pathways modulating cardiomyocyte apoptosis and viability may provide a basis for novel therapeutic approaches. ..
  11. Analysis of Ras and Rho Activation in Prostate Cancer
    Gerry Boss; Fiscal Year: 2005
    ..We now propose to study two large series of prostate cancers, one prospectively and one retrospectively, in order to test these two hypotheses. ..
  12. ACTIVATION SPECIFIC C ERBB 2 DETECTION IN BREAST CANCER
    Richard Epstein; Fiscal Year: 1993
    ....
  13. Streamlined Template Preparation for Advanced Sequencing Methods
    Steven Gordon; Fiscal Year: 2009
    ..The proposed system will be compatible with a number of next generation systems which are starting to enter the market. ..
  14. REGULATION OF BRCA1 SIGNALING AND FUNCTION BY HEREGULIN
    Hava Avraham; Fiscal Year: 2001
    ..In addition, these studies will provide a scientific basis for the manipulation of BRCA 1 for the treatment of this disease. ..
  15. Digital Gene Expression for Cancer
    Steven Gordon; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  16. ETIOLOGY AND PATHOGENESIS OF MULTIPLE SCLEROSIS
    Abdolmohamad Rostami; Fiscal Year: 2000
    ..These receptors are relevant to the growth and maturation of oligodendrocytes and the ligands, which bind the receptors may be relevant to oligodendrocyte injury or enhancement of remyelination in MS. ..
  17. LIPOSOMAL BCL-2 ANTISENSE THERAPY FOR SOLID TUMORS
    Francisco Esteva; Fiscal Year: 2003
    ..Gabriel Lopez-Berestein (Department of Bioimmunotherapy). M. D. Anderson Cancer Center has the patients and resources necessary for Dr. Esteva to successfully complete this research project. ..
  18. Adhesion signaling by a novel mitotic substrate of src
    Mark Moasser; Fiscal Year: 2009
    ..abstract_text> ..
  19. Pilot studies to develop probes for in vivo imaging of P13K/Akt pathway activity
    Mark Moasser; Fiscal Year: 2008
    ..If successful, this modality could potentially lead to a ground-breaking predictive clinical monitoring tool. ..
  20. Changes in Functional Status Across Therapy for Primary Glioma
    Lee Jones; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  21. Antiestrogenic Effects on Tumor Angiogenesis
    Kimberly Blackwell; Fiscal Year: 2006
    ..The results of this project will have profound implications, especially as clinicians begin to use the newer estrogen receptor modulating drugs for the prevention and treatment of breast cancer. ..
  22. CD44-P185HER2 INTERACTION IN OVARIAN CANCER PROGRESSION
    LILLY BOURGUIGNON; Fiscal Year: 2007
    ..abstract_text> ..
  23. Funtional Proteomics and Response to Preoperative Theraphy in Breast Cancer
    Ana Gonzalez Angulo; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  24. Preoperative chemotherapy for breast cancer
    Lajos Pusztai; Fiscal Year: 2007
    ..We expect that our work will lead to the development of microarray-based clinical tests to personalize chemotherapy selection for an individual with newly diagnosed breast cancer. ..
  25. First International Inflammatory Breast Cancer Conference
    Massimo Cristofanilli; Fiscal Year: 2008
    ..For project details please see "Conference Plan". [unreadable] [unreadable] [unreadable]..
  26. CHEMOIMMUNOTHERAPY FOR BREAST CANCER TREATMENT
    Leisha Emens; Fiscal Year: 2006
    ..abstract_text> ..
  27. CD44/VARIANT CYTOSKELETON IN BREAST CANCER PROGRESSION
    LILLY YW BOURGUIGNON; Fiscal Year: 2010
    ....
  28. Tilting the balance in cancer immunotherapy and autoimmunity
    Wei Zen Wei; Fiscal Year: 2010
    ..Establish a vaccination regimen to inhibit spontaneous tumorigenesis and tumor metastasis, and 3. Amplify the immunogenicity of a growing tumor by in situ transfection with TetC DNA. ..
  29. "Ligand Independent" endocrine disruption by pesticides
    Patrick Wong; Fiscal Year: 2005
    ..abstract_text> ..
  30. ANDROGEN SYNTHESIS INHIBITORS FOR PROSTATE CANCER
    Angela Brodie; Fiscal Year: 2008
    ..Determine effective doses, scheduling, and route of administration and b. Compare the effect of lead inhibitors and castration on apoptosis to identify the best compound. ..
  31. Mechanisms by which Polarity Proteins Regulate Initiation and Progression of Brea
    Senthil Muthuswamy; Fiscal Year: 2008
    ..Thus the goal of this proposal is to take a new perspective - understand carcinoma initiation and progression as a function of deregulated cell polarity pathways. ..
  32. GeneRx - colorectal cancer recurrence prediction
    STEVEN LINKE; Fiscal Year: 2008
    ..It should lead to improvements in both survival and quality of life for colorectal cancer patients. [unreadable] [unreadable] [unreadable]..
  33. Epithelial-stromal cell interactions in breast cancer
    Kornelia Polyak; Fiscal Year: 2010
    ....
  34. MOLECULAR ANALYSIS OF THE ALPHA6-BETA4 INTEGRIN
    Filippo Giancotti; Fiscal Year: 2002
    ..We hope that these studies will help to clarify the function of alpha6beta4 in normal and neoplastic cells. ..
  35. Multi-label Molecular FLIM of Breast Cancer
    Jonathan Brown; Fiscal Year: 2008
    ..Specific Aim III. Perform the goals of Aim II in vivo in murine and human mammary tumors in the mouse. [unreadable] [unreadable] [unreadable]..
  36. METALLOPROTEASE DISINTEGRIN MDC9
    Carl Blobel; Fiscal Year: 2002
    ....
  37. CHROMOGENIC HER-2/NEU GENE AMPLIFICATION ASSAY
    Richard Powell; Fiscal Year: 2003
    ..After design optimization, it will be ported to an automated slide staining instrument. Once performance is optimized, multi-center clinical trials will be conducted to support application for pre-market approval. ..
  38. STRUCTURE FUNCTION & FOLDING OF AN RNA BINDING PROTEIN
    Lynne Regan; Fiscal Year: 2003
    ....
  39. Phase 1b Active Immunotherapy with HER-2 Multi-epitope v
    Pravin Kaumaya; Fiscal Year: 2003
    ..abstract_text> ..
  40. Modulation of ErbB Receptor Tyrosine Kinase Signaling
    Kermit L Carraway; Fiscal Year: 2011
    ..Specific Aim 2 examines the molecular mechanisms by which Muc4 alters receptor trafficking and localization. ..
  41. Dual specificity phosphatases and MAP kinase signaling
    Nicholas Tonks; Fiscal Year: 2009
    ....
  42. Peptide Therapeutic Approaches for Immune Tolerance
    Pravin Kaumaya; Fiscal Year: 2003
    ..abstract_text> ..
  43. A Novel Computational Framework for Individualized Clinical Decision-Making
    Nancy Lan Guo; Fiscal Year: 2010
    ..This study will advance the computational modeling of human genome data in disease for clinical decision-making. ..
  44. HLA classl complex expression in breast cancer immunity
    Keith Knutson; Fiscal Year: 2009
    ..The results will likely lead to the identification of specific molecule associated with antigen presentation that could be either a novel therapeutic target or biomarker of disease outcome. ..
  45. Inhibition of Tumor Progression by Hyaluronan Oligomers
    Bryan Toole; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  46. PROTEIN TYROSINE DEPHOSPHORYLATION & SIGNAL TRANSDUCTION
    Nicholas Tonks; Fiscal Year: 2008
    ..Furthermore, proteomics-based strategies are being developed for PTP identification in biological samples, to define novel therapeutic targets for human disease. ..
  47. CSHL Meeting--Tyrosine Phosphorylation & cell Signalling
    Nicholas Tonks; Fiscal Year: 2005
    ..The subsequent meetings (2003 and 2005) will follow a similar format and will include topics that are highly relevant at the time of the meeting. ..
  48. Anti-tumor mechanism of a dietary and herbal mixture
    Lu Hai Wang; Fiscal Year: 2005
    ..supplement, although the efficacy of SV has so far been shown mainly in the NSCLC patients, based upon its designed anti-tumor and immune enhancing activities, it is anticipated that SV should have a wide spectrum of anti-tumor efficacy ..
  49. 2003 Gordon Conference on Proteins
    Lynne Regan; Fiscal Year: 2003
    ..Finally, the organizers are particularly sensitive to ensuring the full representation of women and minorities in this meeting. ..
  50. TUMOR MARKERS TO PREDICT TREATMENT RESPONSE
    Lynn Dressler; Fiscal Year: 2005
    ..Two subcontracts are included in this proposal, one to support the CALGB Pathology Coordinating Office functions at OSU relevant to this study and the other in support of the molecular studies being performed by USC. ..
  51. The RGS-9 mouse: inducible expression in the striatum
    Cary Lai; Fiscal Year: 2004
    ..Through these efforts, we hope to create a genetic tool that will accelerate the development of therapeutics for the patient with Parkinson's and Huntington's disease. ..
  52. Molecular Analysis-Directed Individualised Therapy in Ad
    George Simon; Fiscal Year: 2005
    ..Patients will be followed till death and survival curves will be generated. ..
  53. Characterization of HIN1 Putative Tumor Suppressor
    Ian Krop; Fiscal Year: 2003
    ..The results of these studies will thus determine the role of HIN-1 as a potential tumor suppressor gene and, since it is inactivated frequently in early BC, may provide an excellent target for preventive intervention. ..
  54. Role of the Fetus in the Initiation of Parturition
    CAROLE MENDELSON; Fiscal Year: 2004
    ..abstract_text> ..
  55. Enzymatic Metallography for Ultrasensitive Biodetection
    Richard Powell; Fiscal Year: 2006
    ..abstract_text> ..
  56. HIN-1,A Novel Putative Breast Tumor Suppressor Gene
    Kornelia Polyak; Fiscal Year: 2006
    ..abstract_text> ..
  57. Discovery and characterization of breast cancer genes
    John Hodgson; Fiscal Year: 2008
    ..Finally, effects on in vivo tumorigenic potential will be assessed by evaluating tumor growth in immunedeficient mice. [unreadable] [unreadable]..
  58. Treatment of Older Patients with Early Breast Cancer
    Arash Naeim; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  59. Multi-Antigen Vaccines for Breast Cancer
    MARY DISIS; Fiscal Year: 2007
    ..abstract_text> ..
  60. Role of the Adaptor Protein Shc in Integrin Signaling
    Filippo Giancotti; Fiscal Year: 2007
    ..DNA microarray analysis of polysome-bound mRNAs will be employed to study the role that matrix control of mRNA translation plays in coordinating cell growth and cell division. ..
  61. INVESTIGATING THE MECHANISMS OF PRB TUMOR SUPPRESSION
    Arnab Chakravarti; Fiscal Year: 2003
    ..Specific Aim number 3: To determine whether the deregulation of E2F dependent transcription is correlated with the tumorigenic potential of RB -/- cells in-vivo. ..
  62. The cholinergic mouse
    Cary Lai; Fiscal Year: 2004
    ..abstract_text> ..
  63. Role of Neuregulin/erbB Signaling in the Adult Heart
    Douglas Sawyer; Fiscal Year: 2009
    ..Ultimately, these studies will lead to an understanding of how myocardial NRG/erbB signaling functions to positively regulate cardiac structure, function, and response to stress. ..
  64. OXIDATIVE STRESS INDUCED APOPTOSIS IN CARDIAC MYOCYTES
    Douglas Sawyer; Fiscal Year: 2002
    ..Finally, he will examine whether transgenic mice over-expressing manganese-dependent superoxide dismutase have increased susceptibility to myocardial apoptosis after myocardial infarction. ..
  65. HB-EGF AND ITS RECEPTORS
    Michael Klagsbrun; Fiscal Year: 2003
    ..abstract_text> ..
  66. Functional Genomics Tools for HER2 heterodimers and Androgen Receptor Signaling
    Anjali Jain; Fiscal Year: 2007
    ..Androgen receptor is one such protein. Our research proposes to develop methods to search for compounds that specifically block the androgen receptor in prostate cancer cells. [unreadable]..